CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Eun-Young Kang; Ashley Weir; Nicola S Meagher; Kyo Farrington; Gregg S Nelson; Prafull Ghatage; Cheng-Han Lee; Marjorie J Riggan; Adelyn Bolithon; Gordana Popovic; Betty Leung; Katrina Tang; Neil Lambie; Joshua Millstein; Jennifer Alsop; Michael S Anglesio; Beyhan Ataseven; Ellen Barlow; Matthias W Beckmann; Jessica Berger; Christiani Bisinotto; Hans Boesmueller; Jessica Boros; Alison H Brand; Angela Brooks-Wilson; Sara Y Brucker; Michael E Carney; Yovanni Casablanca; Alicia Cazorla-Jimenez; Paul A Cohen; Thomas P Conrads; Linda S Cook; Penny Coulson; Madeleine Courtney-Brooks; Daniel W Cramer; Philip Crowe; Julie M Cunningham; Cezary Cybulski; Kathleen M Darcy; Mona A El-Bahrawy; Esther Elishaev; Ramona Erber; Rhonda Farrell; Sian Fereday; Anna Fischer; Maria J Garcia; Simon A Gayther; Aleksandra Gentry-Maharaj; C Blake Gilks; Marcel Grube; Paul R Harnett; Shariska Petersen Harrington; Philipp Harter; Arndt Hartmann; Jonathan L Hecht; Sebastian Heikaus; Alexander Hein; Florian Heitz; Joy Hendley; Brenda Y Hernandez; Susanna Hernando Polo; Sabine Heublein; Akira Hirasawa; Estrid Hogdall; Claus K Hogdall; Hugo M Horlings; David G Huntsman; Tomasz Huzarski; Andrea Jewell; Mercedes Jimenez-Linan; Michael E Jones; Scott H Kaufmann; Catherine J Kennedy; Dineo Khabele; Felix KF Kommoss; Roy FPM Kruitwagen; Diether Lambrechts; Nhu D Le; Marcin Lener; Jenny Lester; Yee Leung; Anna Linder; Liselore Loverix; Jan Lubinski; Rashna Madan; G Larry Maxwell; Francesmary Modugno; Susan L Neuhausen; Alexander Olawaiye; Siel Olbrecht; Sandra Orsulic; Jose Palacios; Celeste Leigh Pearce; Malcolm C Pike; Carmel M Quinn; Ganendra Raj Mohan; Cristina Rodriguez-Antona; Matthias Ruebner; Andy Ryan; Stuart G Salfinger; Naoko Sasamoto; Joellen M Schildkraut; Minouk J Schoemaker; Mitul Shah; Raghwa Sharma; Yurii B Shvetsov; Naveena Singh; Gabe S Sonke; Linda Steele; Colin JR Stewart; Karin Sundfeldt; Anthony J Swerdlow; Aline Talhouk; Adeline Tan; Sarah E Taylor; Kathryn L Terry; Aleksandra Toloczko; Nadia Traficante; Koen K Van de Vijver; Maaike A van der Aa; Toon Van Gorp; Els Van Nieuwenhuysen; Lilian Van-Wagensveld; Ignace Vergote; Robert A Vierkant; Chen Wang; Lynne R Wilkens; Stacey J Winham; Anna H Wu; Javier Benitez; Andrew Berchuck; Francisco J Candido Dos Reis; Anna DeFazio; Peter A Fasching; Ellen L Goode; Marc T Goodman; Jacek Gronwald; Beth Y Karlan; Stefan Kommoss; Usha Menon; Hans-Peter Sinn; Annette Staebler; James D Brenton; David D Bowtell; Paul DP Pharoah; Susan J Ramus; Martin Kobel

Journal article

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Eun-Young Kang, Ashley Weir, Nicola S Meagher, Kyo Farrington, Gregg S Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J Riggan, Adelyn Bolithon, Gordana Popovic, Betty Leung, Katrina Tang, Neil Lambie, Joshua Millstein, Jennifer Alsop, Michael S Anglesio, Beyhan Ataseven, Ellen Barlow, Matthias W Beckmann, Jessica Berger Show all

CANCER | WILEY | Published : 2023

DOI: 10.1002/cncr.34582

Abstract

Background: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large-scale, histotype-specific validation has been performed. The hypothesis was that high-level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC. Methods: Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated. Results: High-level a..

View full abstract

University of Melbourne Researchers

Julie Fereday Author

Nadia Traficante Author

David Bowtell Author

Related Projects (5)

Australian Biospecimen Network-Oncology

Availability of ethically consented, clinically annotated human cancer tissue is a key determinant of the international competitiveness of A..

Molecular Epidemiology of Ovarian Research Institute

PUBLIC ABSTRACT A major obstacle to preventive strategies for ovarian cancer is the lack of recognized modifiable risk factors. Age, a pos..

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

AUSTRALASIAN BIOSPECIMEN NETWORK-ONCOLOGY

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by NCI

Awarded by Fund for Scientific Research-Flanders

Awarded by Senior Clinical Investigator of the Fund for Scientific Research-Flanders

Awarded by Uniformed Services University of the Health Sciences from the Defense Health Program

Awarded by NIH NCI

Awarded by Deutsche Forschungsgemeinschaft

Awarded by MRC

Funding Acknowledgements

S. Ramus is supported by National Health and Medical Research Council of Australia (NHMRC) grant APP2009840. N.S. Meagher is supported by the NSW Ministry of Health and UNSW Sydney under the NSW Health PhD Scholarship Program, and the Translational Cancer Research Network, a translational cancer research center program funded by the Cancer Institute NSW. J. Millstein is funded by NCI grant P30CA014089. S. Heublein was funded by Heuer Stiftung fur medizinische Forschung. M.S. Anglesio is funded through a Michael Smith Foundation for Health Research Scholar Award and the Janet D. Cottrelle Foundation Scholars program managed by the BC Cancer Foundation. BC's Gynecological Cancer Research team (OVCARE) receives support through the BC Cancer Foundation and The VGH+UBC Hospital Foundation. L. Loverix is predoctoral researcher of the Fund for Scientific Research-Flanders (FWO Vlaanderen 1S41921). T. Van Gorp is a Senior Clinical Investigator of the Fund for Scientific Research-Flanders (FWO Vlaanderen 18B2921N). The funding for K.M. Darcy and preparation of tumor samples and clinical samples are from awards HU0001-16-2-0006 and HU0001-21-2-0027 from the Uniformed Services University of the Health Sciences from the Defense Health Program to the Henry M Jackson Foundation (HJF) for the Advancement of Military Medicine Inc. Gynecologic Cancer Center of Excellence Program (PI: Yovanni Casablanca, Co-PI: G. Larry Maxwell). D. Khabele is supported by NIH NCI grants R01CA243511 and R21CA210210. A. Staebler received funding by Deutsche Forschungsgemeinschaft as part of the CRC 685. R.E. was supported by the Interdisciplinary Center for Clinical Research (IZKF; Clinician Scientist Program) of the Medical Faculty FAU Erlangen-Nurnberg. U. Menon and A. Gentry-Maharaj are supported by salary contributions through MRC core funding (MC_UU_00004/01).